Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
IONS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.95 - $64.72
Previous CloseN/A
Volume126.35K
Average Volume (3M)2.87M
Market Cap
$9.72B
Enterprise Value$6.89B
Total Cash (Recent Filing)$2.29B
Total Debt (Recent Filing)$1.42B
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Oct 30, 2025EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding159,391,240
10 Day Avg. Volume2,314,998
30 Day Avg. Volume2,873,032
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)8.88
Price to Sales (P/S)7.41
P/FCF Ratio-9.57
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue7.29
Enterprise Value/Gross Profit7.37
Enterprise Value/Ebitda-36.54
Forecast
1Y Price Target
$71.51Price Target Upside17.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe FDA has granted breakthrough therapy designation to Ionis's ION582 for the treatment of Angelman syndrome, which can expedite the development and review process.
Financial PositionWith $2.3 billion in cash on the balance sheet, Ionis is well positioned to fund operations into a sustainable cash-flow-positive enterprise.
Market PotentialThe anticipated better-than-expected benefit of Olezarsen positions it as a potential blockbuster drug in the US.
Bears Say
Valuation ConcernsDespite shares being up 83% year-to-date, the potential for Ionis to become a sustainable cash-flow-positive enterprise is not adequately reflected in the current valuation.
Ionis Pharmaceuticals News
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $23.95 and its highest was $64.72 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $9.72B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 37 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Jul 30, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of -$0.091 by $0.791.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -1.22.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 159,391,240 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of $0.7 in its last earnings report, beating expectations of -$0.091. Following the earnings report the stock price went up 4.556%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in IONS
Ionis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$71.51 (17.21% Upside)
$71.51 (17.21% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 208.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.74%
12-Months-Change
Fundamentals
Return on Equity
-59.83%
Trailing 12-Months
Asset Growth
10.92%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Company Deck
IONS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong commercial and financial performance, driven by the success of the Tryngolza launch and a robust pipeline. Despite some uncertainties in clinical study outcomes and competitive landscapes, the overall sentiment is positive due to significant revenue growth and strategic execution.View all IONS earnings summariesIONS Revenue Breakdown
60.82% R&D
39.18% Commercial
IONS Stock 12 Month Forecast
Average Price Target
$71.51
▲(17.21% Upside)
Technical Analysis
Alkermes
―
Cytokinetics
―
Sarepta Therapeutics
―
Axsome Therapeutics
―
Krystal Biotech
―
Ownership Overview
0.82% Insiders
43.25% Mutual Funds
0.25% Other Institutional Investors
40.90% Public Companies and
Individual Investors